Primary Site >> Pancreatic Cancer

Gene >> SLC28A1

Journal: Clin Cancer Res. 2003 Oct 15;9(13):5000-8.
Title: Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
Author: Garcia-Manteiga, Jose|Molina-Arcas, Miriam|Casado, F Javier|Mazo, Adela|Pastor-Anglada, Marcal
PMID: 14581375
Journal: Clin Cancer Res. 2010 Jan 1;16(1):320-9.
Title: Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Author: Okazaki, Taro|Javle, Milind|Tanaka, Motofumi|Abbruzzese, James L|Li, Donghui
PMID: 20028759
Journal: Cancer. 2010 Nov 15;116(22):5325-35.
Title: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
Author: Tanaka, Motofumi|Javle, Milind|Dong, Xiaoqun|Eng, Cathy|Abbruzzese, James L|Li, Donghui
PMID: 20665488
Journal: Cancer Res. 2011 Mar 1;71(5):1825-35.
Title: CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.
Author: Bhutia, Yangzom D|Hung, Sau Wai|Patel, Bhavi|Lovin, Dylan|Govindarajan, Rajgopal
PMID: 21343396
Journal: Mol Cancer Ther. 2012 Aug;11(8):1735-46.
Title: Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Author: Avan, Amir|Crea, Francesco|Paolicchi, Elisa|Funel, Niccola|Galvani, Elena|Marquez, Victor E|Honeywell, Richard J|Danesi, Romano|Peters, Godefridus J|Giovannetti, Elisa
PMID: 22622284
Journal: Pharmacogenomics. 2012 Jul;13(9):1023-35.
Title: Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.
Author: Woo, Hye In|Kim, Ka-Kyung|Choi, Hangseok|Kim, Seonwoo|Jang, Kee-Taek|Yi, Jun Ho|Park, Young Suk|Park, Joon Oh|Lee, Soo-Youn
PMID: 22838950
Journal: Oncogene. 2013 Mar 28;32(13):1714-23.
Title: The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Author: Skrypek, N|Duchene, B|Hebbar, M|Leteurtre, E|van Seuningen, I|Jonckheere, N
PMID: 22580602
Journal: Cell Death Dis. 2013 May 30;4:e648.
Title: Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner.
Author: Perez-Torras, S|Vidal-Pla, A|Cano-Soldado, P|Huber-Ruano, I|Mazo, A|Pastor-Anglada, M
PMID: 23722537
Journal: Cancer Chemother Pharmacol. 2013 Sep;72(3):669-82.
Title: The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.
Author: Mohelnikova-Duchonova, Beatrice|Brynychova, Veronika|Hlavac, Viktor|Kocik, Matej|Oliverius, Martin|Hlavsa, Jan|Honsova, Eva|Mazanec, Jan|Kala, Zdenek|Melichar, Bohuslav|Soucek, Pavel
PMID: 23934321
Journal: J Pharmacol Sci. 2015 Mar;127(3):319-25.
Title: Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Author: Minami, Kentaro|Shinsato, Yoshinari|Yamamoto, Masatatsu|Takahashi, Homare|Zhang, Shaoxuan|Nishizawa, Yukihiko|Tabata, Sho|Ikeda, Ryuji|Kawahara, Kohich|Tsujikawa, Kazutake|Chijiiwa, Kazuo|Yamada, Katsushi|Akiyama, Shin-ichi|Perez-Torras, Sandra|Pastor-Ang
PMID: 25837929
Journal: Oncotarget. 2015 May 10;6(13):10853-67.
Title: The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Author: Skrypek, Nicolas|Vasseur, Romain|Vincent, Audrey|Duchene, Belinda|Van Seuningen, Isabelle|Jonckheere, Nicolas
PMID: 25890497